프로톤 펌프 억제제 종류에 따른 비궤양성 소화불량증 환자와 소화성 궤양 환자의 Helicobacter pylori 제균율 비교

홍은정 ( Eun Jung Hong ),박동일 ( Dong Il Park ),오석중 ( Suk Joong Oh ),송민준 ( Min Jun Song ),최우혁 ( Woo Hyuk Choi ),홍철호 ( Cheul Ho Hong ),박정호 ( Jung Ho Park ),김홍주 ( Hong Joo Kim ),조용균 ( Yong Kyun Cho ),손정일 ( C 대한소화기학회 2008 대한소화기학회지 Vol.52 No.2

Background/Aims: Conflicting results have been reported whether patients with non-ulcer dyspepsia (NUD) respond differently to Helicobacter pylori (H. pylori) eradication treatment compared with patients with peptic ulcer diseases (PUD). The aim of this study was to evaluate any difference in H. pylori eradication rates between patients with NUD and PUD according to each proton pump inhibitor (PPI). Methods: From September, 2004 to April, 2007, we retrospectively reviewed 2,297 patients with NUD (1,050 patients) or PUD (1,247 patients) infected with H. pylori. All patients received a standard 1 week triple therapy comprising of one of the five PPIs (pantoprazole, esomeprazole, omeprazole, lansoprazole, rabeprazole), clarithromycin and amoxicillin. The follow-up H. pylori test was performed 4 weeks after the completion of therapy. Results: There was no significant difference in the eradication rates between the two groups. In comparison of eradication rates according to PPI, omeprazolebased triple therapy group showed higher eradication rate than other groups in patients with NUD, but not in patients with PUD. Conclusions: This study failed to show any difference in H. pylori eradication rate between patients with NUD and PUD. There is no convincing evidence that the eradication rate may be affected by different PPI. (Korean J Gastroenterol 2008;52:80-85)

위장암 : 대장암에서 HER-2/neu 발현에 관한 연구

박동일 ( Dong Il Park ),오석중 ( Suk Joong Oh ),박승하 ( Seung Ha Park ),윤중원 ( Jung Won Yun ),김홍주 ( Hong Joo Kim ),조용균 ( Yong Kyun Cho ),성인경 ( In Kyung Sung ),손정일 ( Chong Il Sohn ),전우규 ( Woo Kyu Jeon ),김병익 ( B 대한소화기학회 2004 대한소화기학회지 Vol.44 No.3

목적: HER-2/neu 단백은 상피성장인자 수용체와 구조가 거의 일치하기 때문에 정상 세포의 성장과 증식 과정에 관여한다. 유방암에서 HER-2/neu의 과발현은 나쁜 생존율을 예상할 수 있는 예후인자일 뿐 아니라 항암화학요법이나 호르몬요법에 잘 반응하지 않는 등 치료에 대한 반응을 예측할 수 있는 인자이며 HER-2/neu에 대한 단일클론 항체인 Herceptin(R)은 림프절에 전이된 유방암 환자에서 장기 생존율을 향상시켜 임상에서 활발히 사용되고 Background/Aims: The HER-2/neu protein is involved in normal cell proliferation and tissue growth because it is extensively homologous and related to epidermal growth factor receptor. As a prognostic marker, HER-2/neu is used to forecast the clinical cour

글루코사민 유도체(GD) 급여 돈육의 육질 특성

박범영,조수현,황인호,김진형,오석중,이종문,윤상기,Park Beom-Young,Cho Soo-Hyun,Hwang In-Ho,Kim Jin-Hyoung,Oh Suk-Jung,Lee Jong-Moon,Yun Sang-Gi 한국축산식품학회 2004 한국축산식품학회지 Vol.24 No.3

이유자돈 시기 25∼70일령까지 글루코사민 유도체를 1일 1두당 3 mL급여한 돼지와 급여하지 않은 돼지의 도체등급 특성과 육질특성을 비교한 결과는 다음과 같다. 도체중과 등지방층 두께는 시험구와 대조구간 유의적인 차이를 보이지 않았으나, 시험구가 표준오차가 적어 균일도가 높은 것으로 조사되었다. 도체등급 판정결과 최종 A등급 출현율을 비교했을 경우에는 시험구 및 대조구에서 각각 48.7%, 29.2%로 시험구가 약 19.5% 높은 출현율을 보였다. 돼지고기의 육질을 비교한 결과 육색, 가열감량, 전단력, pH 보수성, 육즙분리율 등 대부분의 육질에서 유의적인 차이를 보이지 않았으나(p>0.05), 일반성분중 단백질과 회분은 시험구가 유의적으로 높은 경향을 보였다. 본 시험결과 이유후 육성돈 시기에 글루코사민 유도체의 급여는 육질에는 큰 차이가 없으나, 출하일령 단축과 도체등 급에서의 규격돈 생산에는 효과가 있는 것으로 나타났다. The feeding group, composed of weaning pigs fed 3 mL of glucosamine derivatives, was compared for the carcass and quality characteristics with the unfeeding control group for 25∼70 days since they were born. The results were as follows; There were no significant differences in carcass weight and back-fat thickness between the feeding group and the unfeeding group although the feeding group had low ranges of standard error when compared to the control. Feeding group had higher incidence frequencies of A grade (42.7%) than the control (29.2%). The feeding group and unfeeding group had no significant differences in meat color, cooking loss, WBS, pH, WHC and purge loss. Results from this study showed that feeding GD had effect on the decrease the market weight and production of consist carcass weight, however, the feeding GD had no effect on pork quality during rearing times after weaning.

토끼에서 D-Luciferin의 관절강 주입에 의한 연골세포의 자연발광 영상

문성민 ( Sung Min Moon ),민정준 ( Jung Joon Min ),오석중 ( Suk Jung Oh ),강한샘 ( Han Saem Kang ),김영호 ( Sung Mi Kim ),김성미 ( Young Ho Kim ),김광윤 ( Kwang Yoon Kim ),범희승 ( Hee Seung Bom ) 대한핵의학회 2007 핵의학 분자영상 Vol.41 No.1

Helicobacter pylori 감염 환자에서 10일 연속 제균치료의 효과

최우혁 ( Woo Hyuk Choi ),박동일 ( Dong Il Park ),오석중 ( Suk Joong Oh ),백유흠 ( Yoo Hum Baek ),홍철호 ( Cheul Ho Hong ),홍은정 ( Eun Jung Hong ),송민준 ( Min Jun Song ),박성근 ( Sung Keun Park ),박정호 ( Jung Ho Park ),김홍주 ( 대한소화기학회 2008 대한소화기학회지 Vol.51 No.5

Background/Aims: Antibiotic resistance and poor compliance are the main causes of Helicobacter pylori (H. pylori) eradication failure. Proton pump inhibitor (PPI)-based triple therapy is the most preferred regimen in clinical practice. However, a critical fall in the H. pylori eradication rate has been observed in the recent years. A novel 10 day-sequential therapy consists of five days of dual therapy followed by five days of triple therapy regimen has recently been described. We aimed to evaluate whether 10 day-sequential therapy eradicated H. pylori infection better than the PPI-based triple therapy in Korea. Methods: 158 patients with proven H. pylori infection were randomized to receive either 10 day-sequential therapy (20 mg of omeprazole, 1.0 g of amoxicillin, each administered twice daily for the first 5 days, followed by 20 mg of omeprazole, 500 mg of clarithromycin, 500 mg of metronidazole, each administered twice daily for the remaining 5 days) or PPI-based triple therapy (20 mg of omeprazole, 1.0 g of amoxicillin, 500 mg of clarithromycin, each administered twice daily for 1 week). Outcome of eradication therapy was assessed 8 weeks after the cessation of treatment. Results: Eradication rates of 10 day-sequential therapy and PPI-based triple therapy were 77.9% (60/77) and 71.6% (58/81) by intention to treat analysis, respectively (p=0.361). By per protocol analysis, eradication rates of 10 day-sequential therapy and triple therapy were 85.7% (60/70) and 76.6% (58/76), respectively (p=0.150). There were no significant differences in adverse event rates and treatment compliance between two groups. Conclusions: The 10 day-sequential therapy regimen failed to achieve significantly higher eradication rates than PPI-based triple therapy. (Korean J Gastroenterol 2008;51:280-284)

지역 특산 천연산물 전호, 파고지, 희첨 및 산수유의 항비만효과 규명

신진혁(Jin Hyuk Shin),차구용(Gu Yong Cha),김희진(Hui Jin Kim),황재호(Jae Ho Hwang),한경호(Kyeong Ho Han),서효진(Hyo Jin Seo),신태선(Tai Sun Shin),오석중(Suk Jung Oh),김종덕(Jong Deog Kim) 한국생물공학회 2009 KSBB Journal Vol.24 No.6

본 연구에서는 신생혈관형성 제어에 바탕을 둔 비만세포 제어 정도를 확인하기 위하여 4가지 지역 천연산물인 전호 (Anthrisci radix), 파고지 (Psoraleae semen), 희첨 (Siegesbeckiae herba) 및 산수유 (Corni fructus)를 이용한 지방 축적물 변화 및 기전을 확인하기 위해 3T3-L1 adipocyte를 이용한 Oil Red O 염색 및 western blot을 실시하였다. 그 결과 전호, 파고지, 희첨, 산수유의 세포 독성 이내의 농도 증가에 따라 지방 축적물이 감소됨을 보였다. 또한 western blot을 위해 lipogenesis와 관련된 SREBP-1 및 adipogenesis와 관련된 PPARγ와 C/EBPα의 신호전달 정도를 확인한 결과 4가지 지역 천연산물의 농도 증가에 따라 단백질의 발현양이 감소 됨을 확인하였다. 이는 4가지 지역 천연산물 추출물이 지방 분화와 관련된 신호분자를 차단함으로써 지방형성이 억제 되었음을 보였다. 따라서 4가지 지역 천연산물인 전호, 파고지, 희첨 및 산수유는 신생혈관형성 억제에 따른 항비만제 제로서의 이용 가능함을 시사하였다. 4 kinds of Regional Special Natural Products (RSNPs), such as Anthrisci radix, Psoraleae semen, Siegesbeckiae herba and Corni fructus were examined to verify for anti-obesity effect. PPARγ (peroxisome proliferator-activated receptor γ) from 3T3-L1 cell concerning adipocyte differentiation was suppressed by different concentraton of 4 RSNPs with western blot, when treated RSNPs" extract and MDI (IBMX, Dexamethasone, Insulin) at the same time. Also, SREBP-1 (Sterol regulatory element binding protein) controlling lipogenesis and PPARγ expression levels were reduced by these 4 RSNPs" extract, when these chemicals after differentiation of 3T3-L1 cell. And lipid droplets were reduced by 7.5%, 14.4%, 18.3% and 30% at different concentration of Anthrisci radix from Oil Red O staining. Also, it was reduced by 2%, 4.9%, 9.3% and 38% at different concentration of Psoraleae semen. For Siegesbeckiae herba, it was inhibited by 1.4%, 6.4%, 16.4% and 30.1%, respectively. And Corni fructus was also showed by 0.9%, 6.3%, 13.7% and 33% at same concentration of Siegesbeckiae herba. These 4 kinds of RSNPs were expected for a useful material for anti-obesity materials.

지역 특산 천연산물 전호, 파고지, 희첨 및 산수유의 동물세포간의 부착 억제효과

신진혁(Jin Hyuk Shin),차구용(Gu Yong Cha),김희진(Hui Jin Kim),황재호(Jae Ho Hwang),한경호(Kyeong Ho Han),서효진(Hyo Jin Seo),김민용(Min Yong Kim),오석중(Suk Jung Oh),김종덕(Jong Deog Kim) 한국생물공학회 2009 KSBB Journal Vol.24 No.6

많은 연구를 통해 세포간 부착은 신생혈관형성에 큰 영향을 미치며, 이러한 세포부착억제를 통해 직접적으로 신생혈관형성을 제어할 수 있다. 따라서 본 연구에서는 이러한 신생혈관형성 억제력을 가지는 지역 천연산물을 이용하여 HUVECs 및 U937 cells를 이용한 세포부착 억제정도를 확인하였다. 4가지 천연산물의 세포부착 억제력을 확인하기 위해 세포부착 억제실험을 3가지 방법으로 달리 하여 세포부착 억제정도를 확인한 결과 먼저, IL-1β 및 천연산물이 자극된 HUVECs 에 대한 U937 세포부착 억제실험에서는 전호, 파고지, 희첨 및 산수유의 농도 증가에 따라 전호의 경우 최고 0.2 mg/L에서 276%의 저해율을, 파고지의 경우 5 mg/L에서 220%, 희첨의 경우 10 mg/L에서 158%, 산수유의 경우 20 mg/L에서 132%의 저해효과가 있음을 보였다. 두 번째로 실시한 HUVECs에 대한 PMA 및 천연산물이 자극된 U937 세포부착 억제실험에서는 전호 0.2 mg/L에서 139%, 파고지 5 mg/L에서 442%, 희첨 10 mg/L에서 720%, 산수유 20 mg/L에서 664%의 저해율을 보임을 확인하였다. 마지막으로 실시한 IL-1β 및 천연산물 추출물이 자극된 HUVECs에 대한 천연산물 추출물이 자극된 U937 cells 의 세포부착 억제실험의 경우, 전호 0.2 mg/L에서 286%, 파고지 5 mg/L에서 146%, 희첨 10 mg/L에서 436%, 산수유 20 mg/L에서 297%의 저해율을 보였다. 이상의 3가지 방법으로 실시한 세포부착 억제실험에서 모두 각각의 천연산물 추출물의 농도증가에 따라 현저하게 그 부착력이 억제됨을 확인하였다. 따라서, 본 연구에서 사용된 전호, 파고지, 희첨 및 산수유는 세포부착을 억제함으로서, 신생혈관형성과 관련된 암 및 비만의 근본적인 치료제제로써 사용 가능함을 시사한다. For investigation of anti-angiogenesis mechanism of Anthrisci radix, Psoraleae semen, Siegesbeckiae herba and Corni fructus, anti-cell adhesion experiment was performed. The adhesion of U937 cells to IL-1β-stimulated HUVECs was completely suppressed by 276% at 0.2 mg/L of Anthrisci radix, 220% at 5 mg/L of Psoraleae semen, 158% at 10 mg/L of Siegesbeckiae herba and 132% at 20 mg/L of Corni fructus, respectively. And the adhesion of PMA-chemical stimulated U937 cells to HUVECs, it was inhibited 139% at 0.2 mg/L of Anthrisci radix, 442% at 5 mg/L of Psoraleae semen, 720% at 10 mg/L of Siegesbeckiae herba and 664% at 20 mg/L of Corni fructus. Also, the adhesion of chemical stimulated U937 cells to IL-1β/chemical stimullated HUVECs, it was inhibited by 286% at 0.2 mg/L of Anthrisci radix, 146% at 5 mg/L of Psoraleae semen, 436% at 10 mg/L of Siegesbeckiae herba and 297% at 20 mg/L of Corni fructus, respectively. It would be a useful substance for anti-cell adhesion based on anti-angiogenesis for anti-obesity and anti-cancer.

Trimethoprim / Sulfamethoxazole ( TMP / SMX ) 을 복용 중인 외래 환자에서 발생하는 경구 칼륨 투여 후 칼륨 대사 장애

최춘식(Chun Sik Choi),유영조(Young Jo Yoo),김태영(Tae Young Kim),민경환(Kyung Hwan Min),한상웅(Sang Woong Han),노광호(Kwang Ho Roh),양성규(Seong Kyu Yang),유준호(Jun Ho Yoo),오석중(Suk Joong Oh),문중돈(Jung Don Mun),김호중(Ho Jung Ki 대한내과학회 1999 대한내과학회지 Vol.57 No.1

N/A TMP/SMX has been shown to cause hyperkalemia in a few outpatients on standard-dose. This prospective study was aimed at investigating other associated factors inducing clinically important hyperkalemia in outpatients on standard-dose of TMP/SMX. Methods : Age-matched diabetic(n=22) and non-diabetic (n=20) patients with UTI on standard dose of TMP/SMX for 5 days were given acute oral intake of 40 mEq of potassium chloride(KCl). Results : Before the intake of TMP/SMX, basal levels of serum potassium(K), serum BUN and creatinine, plasma renin activity(PRA), aldosterone(PA), and transtubular potassium gradient(TTKG) were comparable between diabetic and non-diabetic subjects. Also after TMP/SMX was taken, all parameters didnt reveal any overt changes except a slightly increased serum K but not significantly (from 4.20±0.15 to 4.14±0.21mEq/L in non-diabetics; from 4.13±0.18 to 4.25±0.13mEq/L in diabetics). Following acute oral KCl load, however, the peak increases of serum K changes were significantly higher in diabetics compared to non-diabetics(0.34 0.06 vs 0.62 0.09mEq/L, p<0.01). Furthermore, 8 out of 22 diabetics but none of non-diabetics after acute KCl load developed hyperkalemia(> 5.0 mEq/L). After KCl load, PRA did not show any significant changes, whereas PA was increased simultaneously with the increments of serum K in both diabetic subgroups hyperkalemic(n=8) and normokalemic (n=14) diabetics. But increment was blunted in hyperkalemic diabetic subgroup. TTKG was increased prominently in normokalemic diabetic subgroup(9.20 from 4.50), while it was slightly increased in hyperkalemic diabetic subgroup(4.63 from 3.79mEq/L). There was statistical difference between two subgroups(p < 0.05). In conclusion, Besides the known effect of blocking sodium channels in distal K secreting cells by TMP/SMX, insulinopenia(DM). Hypoaldosteronism with its decreased tubular bioactivity, and increased exogenous K intake in concert could cause clinically overt hyperkalemia on standard-dose of TMP/SMX. When standard- dose of TMP/SMX is administered to patients with deranged K homeostasis, especially to diabetics with hypoaldosteronism, blood K level should be monitored meticulously to avoid hyperkalemia.

악성 질환에서의 고용량 화학요법과 자가말초혈액 조혈모세포이식술 : 단일기관 치료 경험

최정혜,안명주,오호석,이웅수,오석중,이영열,최일영,김인순 대한조혈모세포이식학회 2003 대한조혈모세포이식학회지 Vol.8 No.2

연구배경: 고용량 화학요법은 항암제의 투여 용량에 따라 항암효과가 비례하는 용량반응 관계가 있는 악성종양에서 효과를 기대할 수 있으며 현재 급성백혈병, 악성림프종, 다발성골수종 등의 혈액 종양과 유방암, 고환암, 난소암, 신경아세포종 등의 고형암 환자에서 시행되고 있다. 저자들은 고용량화학요법에 이어 자가조혈모세포이식을 시행 받은 악성 종양 환자를 대상으로 치료효과 및 부작용 등의 임상상을 알아보고자 하였다. 방법: 1997년부터 2003년까지 한양대학교 병원에서 자가조혈모세포이식을 시행 받은 악성 종양 환자 31예(남서 : 여성 15 : 16, 중앙연령: 50세, 다발성골수종 14예, 비호지킨림프종 9예, 유방암 4예, 호지킨림프종 3예, 급성골수성백혈병 1예)를 대상으로 후향적 분석을 시행하였다. 결과: 채집된 단핵구의 중앙값은 5.1×10^(8)/kg (범위 1.6~189.3)이었고 CD34양성세포수의 중앙값은 12.0×10^(6)/kg (범위 1.3~75.1)이었다. 말초혈액 과립구가 500/μL 에 도달하는 중앙값은 11일(범위 8~27)이었고 혈소판이 20,000/μL에 도달하는 중앙값은 11일(범위 0~32)이었다. 고용량 항암화학요법 후 21예가 완전관해, 5예가 부분관해에 도달하였다. 생존한 환자의 중앙추적기간은 29.5개월이었고 전체 환자의 2년 무병생존기간은 55.7%이었고 중앙값은 48.2개월이었다. 2년 생존기간은 62.9%이었으며 중앙값에는 도달하지 않았다. 10예의 사망환자 중 7예가 질병의 진행으로 사망하였고, 조기사망 3예(심부전과 신부전 1예, 장파열 1예, 패혈증 1예)가 있었다. 결론: 이 연구는 포함된 환자의 수가 적고 추적기간이 짧은 단점이 있으나, 다발성골수종, 악성림프종 등의 악성 질환에서 고용량 항암화학요법과 자가조혈모세포이식은 안전하고 효과적인 치료임을 추정할 수 있었다. Background: We performed the current study to evaluate the safety and efficacy of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell transplantation (ASCT) in malignant diseases. Methods: Between January 1997 and March 2003, 31 patients (14 multiple myeloma, 9 Non-Hodgkin's lymphoma, 3 Hodgkin's disease, 4 breast cancer, and 1 acute myelogenous leukemia) underwent HDC with ASCT. Stem cells were collected by CS-3000 after mobilization treatment with chemotherapy and granulocyte colony-stimulating factor. The conditioning regimens included high-dose melphalan, BEAM (BCNU, etoposide, cytosine arabinoside, melphalan), BEAC (BCNU, etoposide, cytosine arabinoside, cyclophosphamide), CPB (cyclophosphamide, cisplatin, BCNU) and others. Results: There were 15 male and 16 female patients and median age was 50 years (range: 29~77). The median number of mononuclear and CD34+ cells was 5.1×10^(8)/kg (1.6~189.3) and 12.0×10^(6)/kg (1.3~75.1), respectively. The median time of neutrophil (>500/μL) and platelet (>20,000/μL) engraftment was 11 (8~27) and 11 (0~32) days after ASCT, respectively. Twenty-two patients experienced neutropenic fever. Twenty-one patients achieved complete remission and 5 patients achieved partial remission after HDC with ASCT. The median follow-up duration for surviving patients was 29.5 months. Causes of death included disease progression (7), sepsis (1), bowel perforation (1), and renal failure (1). Median progression free survival (PFS) was 48.2 months and median overall survival (OS) was not reached. Two-year PFS and OS was 55.7% and 62.9%, respectively. Conclusion: Our results suggest that HDC with ASCT was safe and effective modality in patients with various malignant diseases.